Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, single-ascending dose and two-way crossover food effect study to determine the safety, tolerability, pharmacokinetics and food effect of ATN-249 in healthy male participants

Trial Profile

A randomized, double-blind, placebo-controlled, single-ascending dose and two-way crossover food effect study to determine the safety, tolerability, pharmacokinetics and food effect of ATN-249 in healthy male participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs ATN 249 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Attune Pharmaceuticals; LifeSci Pharmaceuticals
  • Most Recent Events

    • 22 Jan 2019 According to an Attune Pharmaceuticals media release, data from this trial (n=48) was presented at the Western Society of Allergy, Asthma and Immunology (WSAAI) 2019 Annual Scientific Session.
    • 22 Jan 2019 Results (n=48) presented in an Attune Pharmaceuticals media release.
    • 02 Jul 2018 According to Australian New Zealand Clinical Trials Registry, the protocol was amended following the approval of HREC to include higher drug strengths.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top